MedTrace Logo

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

NCT04650542 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2022-07-15

No results posted yet for this study

Summary

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

Conditions

  • Drug-drug Interaction

Interventions

DRUG

HBI-3000

small molecule, multi-ion channel blocker

DRUG

Paroxetine

serotonin uptake inhibitor, CYP2D6 inhibitor

Sponsors & Collaborators

  • HUYABIO International, LLC.

    lead INDUSTRY

Principal Investigators

  • Jason Lickliter, MD · Nucleus Network

  • Jennifer Deering, MSN, ARNP · Spaulding Clinical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-21
Primary Completion
2021-08-13
Completion
2021-08-13
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04650542 on ClinicalTrials.gov